X

Trial Profile

A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for up to 60 Months to Adult Fabry Patients

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegunigalsidase alfa (Primary)
Indications Fabry's disease
Focus Adverse reactions; Therapeutic Use
Sponsors Protalix Biotherapeutics

Most Recent Events

03 Feb 2022 According to a Protalix BioTherapeutics media release, results from this study will be presented by Dr. Derralynn Hughes at the 18th Annual WORLDSymposium™ 2022.
20 Jan 2022 Status changed from active, no longer recruiting to completed.
10 Nov 2020 This trial has been completed in United Kingdom, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com